U.S. markets closed

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.68+0.05 (+0.58%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.63
Open8.70
Bid8.50 x 1100
Ask9.16 x 800
Day's Range8.56 - 8.90
52 Week Range7.63 - 17.62
Volume532,687
Avg. Volume173,998
Market Cap536.598M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event
      PR Newswire

      Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event

      Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Eric Ostertag, M.D., Ph.D., Poseida Therapeutics' Chief Executive Officer, will participate in a pre-recorded presentation through the SternIR Virtual Corporate Access Event taking place from January 11-14, 2021. In addition, management will be available for one-on-one meetings with investors.

    • Poseida Therapeutics Added to NASDAQ Biotechnology Index
      PR Newswire

      Poseida Therapeutics Added to NASDAQ Biotechnology Index

      Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). Addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

    • Poseida Therapeutics Appoints Luke Corning to Board of Directors
      PR Newswire

      Poseida Therapeutics Appoints Luke Corning to Board of Directors

      Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Luke Corning, Portfolio Manager and Head of Credit at Pentwater Capital Management, to its Board of Directors.